General presentation of the Pfizer Company:
The Pfizer Group is the international leader in pharmaceuticals at the present time. Its activities can be separated into several categories including medicines for the treatment of cardiovascular illnesses, nervous system problems, infectious illnesses, urology, ophthalmology and also vaccines and oncology products.
The majority of its turnover is achieved in the United States and Europe.
Know the competitors of Pfizer shares:
The Pfizer group has recorded slightly smaller sales figures over the last few years but retains the number one position worldwide in pharmaceuticals at present. In terms of turnover it is still the largest company in this sector.
Strategic alliances implemented by the Pfizer Group:
Pfizer has also developed favourable alliances with some major companies and formed strategic partnerships.
- Zhejiang Hisun: In 2012, Pfizer became notably associated with the Chinese company Zhejiang Hisun in order to obtain high quality generic medicines at low prices for the Chinese market.
- Matwin: In 2015, the Pfizer group became one of the partners of the MATWIN Company that specialises in oncology projects and is part of the UNICANCER group, thereby joining the ten other member laboratories that participate in this research project.
- IBM: In 2016, Pfizer also became associated with the IT company IBM in the creation of remote monitoring solutions for patients suffering from Parkinson’s disease.
Introduction and quotation of the Pfizer share price:
The Pfizer share price is currently quoted on the NYSE ARCA Europe stock market in the Netherlands and is also integrated in the calculation of the Dow Jones stock market Index.
Over the last decade we notice two major movements on the historical stock market charts. The first is marked by a downtrend from 2005 to 2010. After this period we can observe a general rising trend that seems to be continuing at present and should remain so over the long term.
Stock market information
As well as the useful information you read above such as the current share price and Pfizer’s share price history we now offer you the opportunity to learn more about this company and its position on the stock market. So here is some general information on the company as well as its share price on the stock markets.
- In 2017, the total stock market capital of the Pfizer Company achieved 196,280.94 million U.S. dollars.
- The number of shares issued by the Pfizer Company and currently in circulation on the stock markets is 5,955,000,000.
- The Pfizer share price is currently quoted on the Main Market of the NYSE stock Market in the United States.
- The Pfizer Company is of course also included in the composition of the American Dow Jones Industrial Average stock market index.
- The major shareholdings in the Pfizer Company are as follows: 6.62% Vanguard Group, 5.28% State Street Corporation, 3.81% Black Rock Fund Advisors, 1.33% T. Rowe Price Associates, 1.32% Northern Trust Investments, 1.29% J P Morgan Investment Management, 1.20% State Street Global Advisors, 1.13% Wellington Management Company, 0.98% State Farm Mutual Automobile Insurance Company and 0.96% Norges Bank.
- In 2007 the CEO of Pfizer announced a planned cutback of 10,000 jobs representing 10% of the group’s total workforce before 2008.
- In 2009 the group purchased Wyeth for the sum of 68 billion dollars paid for with assets, loans and cash. In the same year Pfizer and its subsidiary Pharmacia & Upjohn Company paid a fine of 2.3 billion dollars to stop the complaints relating to their commercial and advertising policies.
- In 2013 the Pfizer Group withdrew capital from its animal health subsidiary company Zoetis which then became independent.
- In 2014 Pfizer tried to buyout Astrazeneca with an offer of 100 billion dollars which was then increased to 117 billion dollars but the company finally refused. Still in 2014, Pfizer proceeded with the purchase of two vaccines, the NeisVac-C and the FSME-IMMUN from the Baxter Laboratory for the sum of 635 million dollars.
- In 2015 Pfizer purchased the Hospira Company, valued at 17 billion dollars for the amount of 90 dollars per share. In the same year the group started negotiations for the purchase of the Allergan Group in order to move the registered office of the company outside the United States. This offer valued Allergan at 160 billion dollars.
- In 2016 the American Treasury implemented new regulations aimed at avoiding the redomiciliation of Pfizer which would lead to the cancelation of the Allergan purchase. Still in 2016, the Pfizer group announced the takeover of Anacor, specialists in the treatment of eczema using gels for the sum of 5.2 billion dollars. Pfizer then announced the buyout of Bamboo Therapeutics, specialised in gene therapy, for the amount of 645 million dollars which was followed by the takeover of Medivation, an American biotechnical company that specialises in cancer, for the sum of 14 billion dollars.
- Still in 2016, Astrazeneca announced a new agreement with Pfizer for the sale of part of its activities in the antibiotics sector outside the United States for a sum of nearly 1.5 billion dollars. At the end of the same year Pfizer announced the sale of its perfusion activities related to the purchase of Hospira, at ICU Medical, for the amount of one billion dollars comprised of 600 million dollars in liquidity and 400 million dollars in shares.
The advantages and strengths of the Pfizer share as a stock market asset :
First of all, it is important to remember that the Pfizer Group is one of the giants of the pharmaceutical industry throughout the world. It has been able to achieve this very advantageous positioning thanks to a very strong international presence, as it operates in more than fifty different countries.
This brings us to another of the company's assets, which this time concerns the good geographical distribution of its sources of revenue. By marketing its products throughout the world, Pfizer ensures good protection against geo-economic risks over the long term.
Of course, another strength of the Pfizer Group is its capacity for innovation, which enables it to stand out effectively from the competition by developing products that are both innovative and respond to new consumer needs. To achieve this goal, Pfizer naturally invests a great deal of money in research and development and employs highly qualified researchers.
In addition, the economic and financial history of the company shows that the Pfizer Group has often been involved in mergers and acquisitions of major pharmaceutical brands around the world. This strategy has, of course, provided the company with a significant expansion and has contributed to strengthening its brand image.
The Pfizer brand is in itself an undeniable asset of the group since it is known worldwide and is associated with a rather positive image among patients, doctors and other pharmacists.
Finally, the Pfizer Group's large workforce of more than 100,000 employees throughout its organisation is of course also an advantage for the future of the group, which can thus respond effectively to demand and new market needs, both in terms of production and development.
Disadvantages and weak points of the Pfizer share as a stock market asset :
First of all, the level of competition in which the Pfizer Group operates is of course a major handicap for its growth opportunities. Indeed, the major pharmaceutical groups mentioned above, which compete directly with Pfizer, are waging a fierce war to retain and take market share. It is therefore particularly difficult for Pfizer to increase its sales in any significant way outside of the release of innovative products or the filing of patents.
Finally, Pfizer's second and last weak point concerns its brand image, which has recently been altered. Indeed, the image of this group has become increasingly negative in the eyes of consumers since the company was accused of having participated in the largest health fraud. The group illegally marketed one of its medicines, causing both mistrust among its customers and also mistrust in the market and among investors who are now reluctant to buy the stock.